Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta‐analysis

The optimal antithrombotic regimen in patients with a concomitant indication for oral anticoagulation (OAT) presenting with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) remains unclear.

[1]  F. Gaita,et al.  Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention , 2020, European heart journal. Acute cardiovascular care.

[2]  A. Goette,et al.  Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. , 2019, European heart journal.

[3]  C. Granger,et al.  Stent Thrombosis in Patients with Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. , 2019, Circulation.

[4]  A. Goette,et al.  Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial , 2019, The Lancet.

[5]  Deepak L. Bhatt,et al.  Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. , 2019, JAMA cardiology.

[6]  H. Eisen,et al.  Anti-thrombotic therapy strategies with long-term anticoagulation after percutaneous coronary intervention – a systematic review and meta-analysis , 2019, Journal of community hospital internal medicine perspectives.

[7]  A. Parkhomenko,et al.  Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation , 2019, The New England journal of medicine.

[8]  A. Alexandrov,et al.  Fatal oral anticoagulant‐related intracranial hemorrhage: a systematic review and meta‐analysis , 2018, European journal of neurology.

[9]  G. Stone,et al.  Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients , 2017, European heart journal.

[10]  Deepak L. Bhatt,et al.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation , 2017, The New England journal of medicine.

[11]  G. Lip,et al.  Stroke prevention in atrial fibrillation: Past, present and future , 2017, Thrombosis and Haemostasis.

[12]  G. Lip,et al.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.

[13]  J. Eikelboom,et al.  Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. , 2016, The American journal of medicine.

[14]  G. Stone,et al.  Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents. , 2016, The American journal of cardiology.

[15]  Gerta Rücker,et al.  Ranking treatments in frequentist network meta-analysis works without resampling methods , 2015, BMC Medical Research Methodology.

[16]  J. DiNicolantonio,et al.  Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. , 2015, The American journal of cardiology.

[17]  H. Schunkert,et al.  Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. , 2015, Journal of the American College of Cardiology.

[18]  Tom Adriaenssens,et al.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.

[19]  M. Borggrefe,et al.  Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography , 2011, PloS one.

[20]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[21]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[22]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.